Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
At Build to Last 2026, Saint-Gobain Vietnam announced it has achieved “Zero Carbon” manufacturing for its DURAflex fiber cement sheet plant in Quảng Trị, with no carbon emissions for Scope 1 and Scope 2. The company said it is the first in its industry to reach this milestone. The Zero…
The Gross Law Firm has issued a notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST) regarding a potential securities class action. Shareholders who purchased AQST shares during the class period are encouraged to contact the firm about possible lead plaintiff appointment. Appointment as lead plaintiff is not required to participate in any recovery.
June 16, 2025 to January 8, 2026
According to the complaint, the defendants provided investors with positive statements while allegedly disseminating materially false and misleading statements and/or concealing material adverse facts related to Aquestive’s New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film.
The complaint alleges that Aquestive concealed or minimized the significance of human factors involved in the use and deployment of the sublingual film, including packaging, use, administration, and labeling.
On January 9, 2026, Aquestive announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that precluded labeling discussions for Anaphylm. The company also disclosed that the FDA letter confirmed the agency’s review of the Anaphylm NDA was ongoing and that no final decision had been made, which the notice states effectively delayed approval beyond the January 31, 2026 Prescription Drug User Fee Act date.
Following the January 9, 2026 announcement, the notice states that AQST’s stock price declined sharply. It fell from a closing market price of $6.21 per share on January 8, 2026 to $3.91 per share on January 9, 2026, a decline of over 37% in a single day.
The deadline to seek lead plaintiff status is May 4, 2026.
Shareholders who register as having purchased AQST shares during the class period will be enrolled in a portfolio monitoring software system to receive status updates throughout the lifecycle of the case. The notice states there is no cost or obligation to participate.
The notice describes the Gross Law Firm as a nationally recognized class action law firm focused on protecting investors’ rights. It states the firm seeks recovery on behalf of investors who allegedly incurred losses due to false and/or misleading statements or the omission of material information that led to artificial inflation of a company’s stock.
Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
